1Johnson CD, kingsnorth AN, Imrie CW, et al. Double blind,randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis[J ]. Gut 2001; 48;62-9.
2Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.0 [updated July 1999]; Section 6. In: The Cochrane Library[ database on CDROM]. The Cochrane Collaboration. Oxford:Update Software; 2000, Issue 1.
3British Biotech files 1^st drug approval[J]. Scrip 1997; 2214:17.
4Formark CE, Toskes PP. Acute pancreatitis- medical management[J]. Crit Care Clin 1995; 11:295-309.
5Brady I, Christmas S, Sulton R, et al. Cytokines and acute pancreatitis Baillieres Best Pratt Res[J] Clin Gastroenterol 1999;Jul, 13(2) :265 - 89.
6Norman J. The role of cytokines in the pathogenesis of acute pancreatitis[]]. Am J Surg 1998; 175(1): 76-83.
7Edward L, et al. A clinically based classification system for acute pancreatitis[J]. Arch Surg 1993; 128(5) :586 - 90.
8Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positive results? A systematic review of controlled trials[J ]. Control Clin Trials 1998; 19:159 - 66.
9kingsnorth AN, Gallowau SW, Formela LJ. Randomized, double-blind phase Ⅱ trial of lexipafant, a platdet - activating factor antagonist, in human acute pancreatitis[J]. Br J Surg 1995; 82:1414 - 20.
10Mckay CJ, Curran F, Sharpies C, et al. Prospective placebocontrolled randomized trial of lexipafant in predicted severe acute pancreatits[J]. Br J Surg 1997; 84:1239-43.
